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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To review the effects of oral health advice for people with serious mental illness.
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B A C K G R O U N D
Description of the condition
The deﬁnition of severe mental illness with the widest consen-
sus is that of the National Institute of Mental Health (NIMH)
(Schinnar 1990) and is based on diagnosis, duration and disability
(NIMH 1987). People with serious mental illness have conditions
such as schizophrenia or bipolar disorder, over a protracted pe-
riod of time resulting in erosion of functioning in day to day life.
A European survey put the total population-based annual preva-
lence of serious mental illness at approximately two per thousand
(Ruggeri 2000). Evidence suggests that those with serious mental
illness have a signiﬁcantly increased chance of experiencing oral
health problems than the general population Stiefel 1990; BSDH
2000). Oral health has not been seen as a priority in this group,
although poor dental hygiene impacts on quality of life, affecting
everyday functioning such as eating, comfort, appearance, social
acceptance and self esteem, it is unlikely to be fatal (Cormac 1999).
Poor oral health, however, has been linked to coronary heart dis-
ease (Montebugnoli 2004) and oral health is an important part of
overall physical health. Many drugs routinely prescribed to those
with serious mental illness lead to changes in physiology, some of
which can be dangerous; the recognition of this has largely driven
the monitoring of physical health symptoms in this client group.
In particular, antipsychotics, antidepressants and mood stabilisers
can cause xerostomia (drymouth) which causes changes to the oral
environment leading to periodontal disease (Friedlander 2002).
Description of the intervention
Oral health advice can take many forms depending on environ-
mental and socioeconomic factors. Advice is the active provision
of preventative information; it has an educative component and is
delivered in a gentle non-patronising manner (Stott 1990). There-
fore oral health advice could be deﬁned as any verbal advice about
oral health from a healthcare professional.
How the intervention might work
Advice from a healthcare professional can have a positive impact
on behaviour (Kreuter 2000, Russell 1979). Advice may motivate
people to seek further support and treatment (Sutherland 2003).
Given the evidence of increased rates of potentially preventable
health problems in people with serious mental illness (Cournos
2005, Dixon 1999, Robson 2007), and the suggestion from a
systematic review (Bradshaw 2005) that methodologically robust,
healthy living interventions give “promising outcomes” in people
with schizophrenia, we believe that appropriate oral health advice
could improve the quality and duration of life for sufferers of se-
rious mental illness. Oral health advice from a healthcare profes-
sional may encourage those with serious mental illness to brush
their teeth on a regular basis, have regular dental check-ups and
seek help in a dental emergency.
Why it is important to do this review
Those with serious mental illness are less likely to seek medical
advice and are more likely to be exposed to medications with po-
tentially negative health consequences (Weinmann 2009). Those
with serious mental illness also should stand to beneﬁt from any
oral health advice as there is evidence to suggest they have a greater
risk of experiencing oral disease and have greater oral treatment
needs than the general population (BSDH 2000). Oral health
problems are not well recognised by mental health professionals
and people with serious mental illnesses can experience barriers
to treatment (Cormac 1999) including low tolerance to their lack
of compliance with oral hygiene, and a lack of understanding of
mental health problems from dental professionals (BSDH 2000).
It is important to complete this review because medication used to
treat mental illness may predispose to dental disease and this can
have both local and systemic effects. We know of no systematic
review of oral health advice for those with serious mental illness.
O B J E C T I V E S
To review the effects of oral health advice for people with serious
mental illness.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all relevant randomised controlled trials, and eco-
nomic evaluations conducted alongside included randomised con-
trolled trials.We excluded quasi-randomised studies, such as those
allocating by using alternate days of the week. When we encoun-
tered trials described in some way as to suggest or imply that the
study was randomised and where the demographic details of each
group’s participants were similar, we included them and a sensi-
tivity analysis was undertaken to the presence or absence of these
data.
Types of participants
We required that a majority of participants should be within the
age range 18 to 65 years and suffering from severe mental ill-
ness preferably as deﬁned by National Institute of Mental Health
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(NIMH 1987) but in the absence of this, from diagnosed illnesses
such as schizophrenia, schizophrenia-like disorders, bipolar disor-
der, or serious affective disorder. We did not consider substance
abuse to be a severe mental disorder in its own right, however
we did feel that studies should remain eligible if they dealt with
people with dual diagnoses, that is those with severe mental ill-
ness plus substance abuse. We did not include studies focusing on
dementia, personality disorder and mental retardation as they are
not covered by our deﬁnition of severe mental illness.
Types of interventions
1. Oral health advice
We have found it difﬁcult to ﬁnd a useful deﬁnition of ’advice’. In
the context of this review we deﬁne oral health advice as preventa-
tive information (Greenlund 2002) or counsel (OED) that enables
the recipient to make the ﬁnal decision about their oral health. It
should have at least a suggestion of: i. an educative component; ii.
a preventative aim; and iii. an ethos of self-empowerment. Advice
may be directional but not paternalistic in its delivery. It is not a
programmed or training approach, focusing on the acquisition of
knowledge, skills, and competencies as a result of formal teaching
sessions.
2. Standard care
Care in which oral health advice is not speciﬁcally emphasised
above and beyond the care that would be expected for people
suffering from severe mental illness.
Types of outcome measures
Primary outcomes
1. Oral health
1.1 Not owning a toothbrush
1.2 Not having seen a dentist in the past year
1.3 Not brushing teeth twice a day
1.4 Not ﬂossing teeth twice a day
2. Quality of life
2.1 Loss of independence
2.2 Loss of Activities of Daily Living (ADL) skills
2.3 Chronic pain
2.4 Immobility
2.5 Loss of earnings
2.6 Loss of social status
2.7 Healthy days
Secondary outcomes
1. Adverse events
1.1 Number of participants with at least one adverse effect
1.2 Clinically important speciﬁc adverse effects (cardiac effects,
death, movement disorders, prolactin increase and associated ef-
fects, weight gain, effects on white blood cell count)
1.3 Average endpoint speciﬁc adverse effects score
1.4 Average change in speciﬁc adverse effects score
1.5 Death - natural or suicide
2. Service use
2.1 Hospital admission
2.2 Emergency medical/dental treatment
2.3 Use of emergency services
3. Financial dependency
3.1 Claiming unemployment beneﬁt
3.2 Claiming ﬁnancial assistance because of a physical disability
4. Social
4.1 Unemployment
4.2 Social isolation as a result of preventable incapacity
4.3 Increased burden to caregivers
5. Quality of life/satisfaction with treatment
5.1 No clinically important change in general quality of life
5.2 Average endpoint general quality of life score
5.3 Average change in general quality of life score
5.4 No clinically important change in general functioning
5.5 Average endpoint general functioning score
5.6 Average change in general functioning score
6. Economic
6.1 Increased costs of health care
6.2 Days off sick from work
6.3 Reduced contribution to society
6.4 Family claiming care allowance
7. Leaving the study early (any reason, adverse events, inefﬁcacy
of treatment)
8. Global state
8.1 No clinically important change in global state (as deﬁned by
individual studies)
8.2 Relapse (as deﬁned by the individual studies)
9. Mental state (with particular reference to the positive and neg-
ative symptoms of schizophrenia)
9.1 No clinically important change in general mental state score
9.2 Average endpoint general mental score
9.3 Average change in general mental state score
9.4 No clinically important change in speciﬁc symptoms (positive
symptoms of schizophrenia, negative symptoms of schizophrenia)
9.5 Average endpoint speciﬁc symptom score
9.6 Average change in speciﬁc symptom score
10. Dental state
10.1 Increased plaque index
10.2 Teeth lost due to decay
10.3 Increase in dental caries
10.4 Increase in periodontal disease
10.5 Increase in oral infections
Search methods for identification of studies
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Electronic searches
Electronic searches Cochrane Schizophrenia Group Trials Register
(October 2009)
The register was searched using the phrase:[(*physical* or *cardio*
or *metabolic* or *weight* or *HIV* or *AIDS* or *Tobacc* or
*Smok* or *sex* or *medical* or *dental* or *alcohol* or *oral* or
*vision* or *sight*or *hearing* or *nutrition* or *advice* or *mon-
itor* in title of REFERENCES) AND (*education* OR *health
promot* OR *preventi* OR *motivate* or *advice* or *monitor*
in interventions of STUDY)]
This register is compiled by systematic searches ofmajor databases,
hand searches and conference proceedings (see Group Module).
Searching other resources
1. Reference searching
We inspected the references of all identiﬁed studies for other rele-
vant studies.
2. Personal contact
We contacted the ﬁrst author of each included trial for information
regarding unpublished studies, we also contacted the ﬁrst author
of each ongoing study and requested information about current
progress.
Data collection and analysis
Selection of studies
Authors GT and AC screened the results of the electronic search.
WK inspected a random sample of these abstracts, comprising
10% of the total. Where disagreement occurred we resolved this
by discussion, and where there was still doubt, we acquired the full
article for further inspection. We then requested the full articles of
relevant reports for reassessment and carefully inspected them for
a ﬁnal decision on inclusion (see Criteria for considering studies
for this review). In turn GT and AC inspected all full reports
and independently decided whether they met inclusion criteria.
We were not blinded to the names of the authors, institutions
or journal of publication. Where difﬁculties or disputes arose, we
asked another author for help and if it was impossible to decide,
these studies were added to those awaiting assessment and the
authors of the papers contacted for clariﬁcation.
Data extraction and management
1. Extraction
Authors GT and AC independently extracted data from included
studies. Again, we discussed any disagreement, documented our
decisions and, if necessary, we contacted the authors of studies for
clariﬁcation. Whenever possible we only extracted data presented
in graphs and ﬁgures, we only included data if two reviewers inde-
pendently had the same result. We made attempts to contact au-
thors through an open-ended request, in order to obtain any miss-
ing information or for clariﬁcation whenever necessary. Where
possible, we extracted data relevant to each component centre of
multi-centre studies separately.
2. Management
2.1 Forms
GT and AC extracted data onto standard, simple forms.
2.2 Data from multi-centre trials
Where possible the authors veriﬁed independently calculated cen-
tre data against original trial reports.
3. Scale-derived data
We included continuous data from rating scales only if:
a. the psychometric properties of the measuring instrument had
been described in a peer-reviewed journal (Marshall 2000); and
b. the measuring instrument was not written or modiﬁed by one
of the trialists for that particular trial; and
c. themeasuring instrument is either i. a self-report or ii. completed
by an independent rater or relative.
4. Endpoint versus change data
We preferred to use scale endpoint data, which typically cannot
have negative values and is easier to interpret from a clinical point
of view. Change data are often not ordinal and are very problematic
to interpret. If endpoint data were unavailable, we used change
data.
5. Skewed data
Continuous data on clinical and social outcomes are often not
normally distributed. To avoid the pitfall of applying paramet-
ric tests to non-parametric data, we aimed to apply the following
standards to all data before inclusion: (a) standard deviations and
means are reported in the paper or obtainable from the authors;
(b) when a scale starts from the ﬁnite number zero, the standard
deviation, when multiplied by two, is less than the mean (as oth-
erwise the mean is unlikely to be an appropriate measure of the
centre of the distribution, (Altman 1996); (c) if a scale starts from
a positive value (such as PANSS which can have values from 30 to
210) the calculation described above will be modiﬁed to take the
scale starting point into account. In these cases skew is present if
2SD>(S-S min), where S is the mean score and S min is the mini-
mum score. Endpoint scores on scales often have a ﬁnite start and
endpoint and these rules can be applied. When continuous data
are presented on a scale which includes a possibility of negative
values (such as change data), it is difﬁcult to tell whether data are
skewed or not. We entered skewed data from studies of less than
200 participants in additional tables rather than into an analysis.
Skewed data pose less of a problem when looking at means if the
sample size is large, and we entered skewed data from large sample
sizes into syntheses.
6. Common measure
To facilitate comparison between trials, we intend to convert vari-
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ables that can be reported in different metrics, such as days in hos-
pital, (mean days per year, per week or per month) to a common
metric (e.g. mean days per month).
7. Conversion of continuous to binary
Where possible, we made efforts to convert outcome measures
to dichotomous data. This could be done by identifying cut-off
points on rating scales and dividing participants accordingly into
’clinically improved’ or ’not clinically improved’. It was generally
assumed that if there had been a 50% reduction in a scale-derived
score such as the Brief Psychiatric Rating Scale (BPRS, Overall
1962) or the Positive and Negative Syndrome Scale (Kay 1986,
Kay 1987), this could be considered as a clinically signiﬁcant re-
sponse (Leucht 2005, Leucht 2005a). If data based on these thresh-
olds were not available, we used the primary cut-off presented by
the original authors.
8. Direction of graphs
Where possible, we entered data in such a way that the area to the
left of the line of no effect indicates a favourable outcome for oral
health advice.
9. Summary of ﬁndings table
We anticipate including the following outcomes in a summary of
ﬁnding table.
9.1 Oral health
-Not having seen a dentist in the past year
-Not brushing teeth twice a day
9.2.Quality of life
-Chronic pain
9.3 Adverse event
- Clinically important speciﬁc adverse effects (cardiac effects,
death, movement disorders, prolactin increase and associated ef-
fects,
weight gain, effects on white blood cell count)
9.4 Service use
-Emergency medical/dental treatment
9.4 Leaving the study early
- Increased costs of health care
9.5 Dental state
- No clinically important change in plaque index
Assessment of risk of bias in included studies
Again working independently, GT and AC assessed risk of bias
using the tool described in the Cochrane Collaboration Hand-
book (Higgins 2008). This tool encourages consideration of how
the sequence was generated, how allocation was concealed, the in-
tegrity of blinding at outcome, the completeness of outcome data,
selective reporting and other biases. We excluded studies where
allocation was clearly not concealed. The risk of bias in each do-
main, and overall, are assessed and categorised into:
A. Low risk of bias: plausible bias unlikely to seriously alter the
results (categorised as ’Yes’ in Risk of Bias table)
B. High risk of bias: plausible bias that seriously weakens conﬁ-
dence in the results (categorised as ’No’ in Risk of Bias table)
C. Unclear risk of bias: plausible bias that raises some doubt about
the results (categorised as ’Unclear’ in Risk of Bias table)
We did not include trials with high risk of bias (deﬁned as at least
3 out of 5 domains categorised as ’No’) in the meta-analysis. If
the raters disagreed, the ﬁnal rating was made by consensus with
the involvement of another member of the review group. Where
inadequate details of randomisation and other characteristics of
trials are provided, we contacted the authors of the studies in
order to obtain further information. Non-concurrence in quality
assessment was reported.
Measures of treatment effect
1. Binary data
For binary outcomes we calculated a standard estimation of the
random-effect risk ratio (RR) and its 95%conﬁdence interval (CI).
It has been shown that RR is more intuitive (Boissel 1999) than
odds ratios and that odds ratios tend to be interpreted as RR by
clinicians (Deeks 2000). Within the Summary of Findings table
we assumed for calculation of the low risk groups that the lowest
control risk applied to all data.We did the same for the assumption
of the highest risk groups. We used the Summary of Findings table
to calculate absolute risk reduction for primary outcomes.
2. Continuous data
2.1 Summary statistic
For continuous outcomes we estimated a random-effect mean dif-
ference (MD) between groups. We preferred not to calculate effect
size measures (standardised mean difference - SMD). However, in
the case of where scales were of such similarity to allow presuming
there was a small difference in measurement, we calculated it and,
whenever possible, we transformed the effect back to the units of
one or more of the speciﬁc instruments.
Unit of analysis issues
1. Cluster trials
Studies increasingly employ ’cluster randomisation’ (such as ran-
domisation by clinician or practice) but analysis and pooling of
clustered data poses problems. Firstly, authors often fail to account
for intra class correlation in clustered studies, leading to a ’unit
of analysis’ error (Divine 1992) whereby p values are spuriously
low, conﬁdence intervals unduly narrow and statistical signiﬁcance
overestimated. This causes type I errors (Bland 1997, Gulliford
1999).
Where clustering is not accounted for in primary studies, we pre-
sented data in a table, with a (*) symbol to indicate the presence of
a probable unit of analysis error. In subsequent versions of this re-
view we will seek to contact ﬁrst authors of studies to obtain intra
class correlation co-efﬁcient of their clustered data and to adjust
for this by using accepted methods (Gulliford 1999). Where clus-
tering had been incorporated into the analysis of primary studies,
we present these data as if from a non-cluster randomised study,
but adjusted for the clustering effect.
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We have sought statistical advice and have been advised that the
binary data as presented in a report should be divided by a ’design
effect’. This is calculated using the mean number of participants
per cluster (m) and the intra class correlation co-efﬁcient (ICC)
[Design effect = 1+(m-1)*ICC] (Donner 2002). If the ICC was
not reported it was assumed to be 0.1 (Ukoumunne 1999).
If cluster studies have been appropriately analysed, taking into ac-
count intra class correlation co-efﬁcient and relevant data docu-
mented in the report, synthesis with other studies would be pos-
sible using the generic inverse variance technique.
2. Cross-over trials
A major concern of cross-over trials is the carryover effect. This
occurs if an effect (e.g. pharmacological, physiological or psycho-
logical) of the treatment in the ﬁrst phase is carried over to the
second phase. As a consequence, on entry to the second phase
the participants can differ systematically from their initial state
despite a wash-out phase. For the same reason cross-over trials are
not appropriate if the condition of interest is unstable (Elbourne
2002). As both effects are very likely in severe mental illness, we
only used data from the ﬁrst phase of cross-over trials.
3. Studies with multiple treatment groups
Where a study involved more than two treatment arms, if rele-
vant, we presented the additional treatment arms in comparisons.
Where the additional treatment arms were not relevant, we did
not reproduce these data.
Dealing with missing data
1. Overall loss of credibility
At some degree of loss of follow up data must lose credibility (Xia
2009). For any particular outcome should than 50% of data be
unaccounted, we did not reproduce these data or use them within
analyses. If, however, more than 50% of those in one arm of a
study were lost, but the total loss was less than 50%, we marked
such data with ’*’ to indicate that such a result may well be prone
to bias.
2. Binary
In the case where attrition for a binary outcome is between 0 and
50% and where these data were not clearly described, we presented
data on a ’once-randomised-always-analyse’ basis (an intention
to treat analysis). Those lost to follow up were all assumed to
have the same rates of negative outcome as those who completed,
with the exception of the outcome of death. A sensitivity analysis
was undertaken testing how prone the primary outcomes were to
change when ’completer’ data only were compared to the intention
to treat analysis using the above assumption.
3. Continuous
3.1 Attrition
In the case where attrition for a continuous outcome is between 0
and 50% and completer-only data were reported, we reproduced
these.
3.2 Standard deviations
Where there are missing measures of variance for continuous data
but exact standard error and conﬁdence intervals are available for
groupmeans, and either ’p’ value or ’t’ value are available for differ-
ences in mean, we calculated a standard deviation value according
to the method described in Section 7.7.3 of the Cochrane Hand-
book (Higgins 2008). If standard deviations were not reported
and could not be calculated from available data, we asked authors
to supply the data. In the absence of data from authors, the mean
standard deviation from other studies was used.
3.3 Last observation carried forward
We anticipated that in some studies themethod of last observation
carried forward (LOCF) would be employed within the study
report. As with all methods of imputation to deal with missing
data, LOCF introduces uncertainty about the reliability of the
results. Therefore, where LOCF data has been used in the trial, if
less than 50% of the data had been assumed, we reproduced these
data and indicated that they are the product of LOCFassumptions.
Assessment of heterogeneity
1. Clinical heterogeneity
To judge clinical heterogeneity, we considered all included studies,
initially without seeing comparison data. We simply inspected all
studies for clearly outlying situations or people which we had not
predictedwould arise. Should such situations or participant groups
arise these will be fully discussed.
2. Methodological heterogeneity
We considered all included studies initially, without seeing com-
parison data, to judge methodological heterogeneity. We simply
inspected all studies for clearly outlying methods which we had
not predicted would arise. Should such methodological outliers
arise these will be fully discussed.
3. Statistical
3.1 Visual inspection
We visually inspected graphs to investigate the possibility of sta-
tistical heterogeneity.
3.2 Employing the I-squared statistic
Heterogeneity between studies was investigated by considering the
I-squared method alongside the Chi2 ’p’ value. The I2 provides an
estimate of the percentage of inconsistency thought to be due to
chance (Higgins 2003). The importance of the observed value of I
2 depends on i. magnitude and direction of effects and ii. strength
of evidence for heterogeneity (e.g. ’p’ value from Chi2 test, or a
conﬁdence interval for I2). An I2 estimate greater than or equal
to 50% accompanied by a statistically signiﬁcant Chi2 statistic,
was interpreted as evidence of substantial levels of heterogeneity
(Section 9.5.2 - Higgins 2008) and reasons for heterogeneity were
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explored. If the inconsistency was high and the clear reasons were
found, we presented data separately.
Assessment of reporting biases
Reporting biases arise when the dissemination of research ﬁndings
is inﬂuenced by the nature and direction of results (Egger 1997).
These are described in Section 10 of the Cochrane Handbook
(Higgins 2008). We are aware that funnel plots may be useful in
investigating reporting biases but are of limited power to detect
small-study effects. We will not use funnel plots for outcomes
where there were ten or fewer studies, or where all studies were
of similar sizes. In other cases, where funnel plots are possible, we
will seek statistical advice in their interpretation.
Data synthesis
Where possible we will employ a random-effect model for anal-
yses. We understand that there is no closed argument for pref-
erence for use of ﬁxed or random-effect models. The random-
effect method incorporates an assumption that different studies
are estimating different, yet related, intervention effects. Accord-
ing to our hypothesis of an existing variation across studies, to
be explored further in the meta-regression analysis despite being
cautious that that random-effects methods does put added weight
onto the smaller of the studies - we favoured using random-effect
model.
Subgroup analysis and investigation of heterogeneity
1. Subgroup analyses
We anticipate no sub-group analyses.
2. Investigation of heterogeneity
2.1 Unanticipated heterogeneity
Should unanticipated clinical or methodological heterogeneity be
obvious we will simply state hypotheses regarding these for future
reviews or versions of this review.Wedonot anticipate undertaking
analyses relating to these.
2.2 Anticipated heterogeneity
We anticipate some heterogeneity for the primary outcomes and
propose to summate all data but also present them separately.
Sensitivity analysis
1. Implication of randomisation
We aim to include trials in a sensitivity analysis if they are described
in some way as to imply randomisation. For the primary outcomes
we will include these studies and if there was no substantive dif-
ference when we added the implied randomised studies to those
with better description of randomisation, we then employed all
data from these studies.
2. Assumptions for lost binary data
Where assumptions have to bemade regardingpeople lost to follow
up (seeDealingwithmissing data) we compared the ﬁndings of the
primary outcomes where we used our assumption and compared
with completer data only. If there is a substantial difference, we
reported results and discussed them but continued to employ our
assumption.
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